Managing brain metastases in advanced HER2-positive breast cancer
Get up to date on the data for emerging treatment options for patients with HER2-positive breast cancer and brain metastases and how they may influence clinical practice by watching these short interviews with breast cancer experts.
- Recognize the unmet needs of patients with advanced HER2-positive breast cancer and brain metastases
- Review the clinical data for emerging treatment options for patients with advanced HER2-positive breast cancer and brain metastases
- Determine how novel HER2-targeted therapies may change the future management of patients with HER2-positive breast cancer and brain metastases
Thomas Powles, ASCO20: JAVELIN Bladder 100 Phase III Interim Analysis
It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma. Questions 1. What have we learned so far from clinical trials […]
Risk Stratification of Patients with Hormone-Receptor Positive Breast Cancer to Optimise Treatment Selection
Watch Prof. Peter Schmid, of the St. Bartholomew Breast Cancer Centre in the UK give his perspective on risk stratification for patients with hormone-receptor positive breast cancer; and ways in which this decision-making can be made less subjective in future.
Improving Outcomes in Pancreatic Cancer
Oncology & Haematology Review (US). 2020;16(1):59–66 DOI: https://doi.org/10.17925/OHR.2020.16.1.59
Pancreatic ductal adenocarcinoma (PDA) is predicted to beat colon cancer in terms of total cancer-related deaths in the USA by this year (2020).1 Given this projected burden of disease, efforts in understanding and developing new treatments for PDA are paramount. In this review, we will summarize the molecular characteristics and mutations thought to be involved with […]
Aiming for new targets in biliary tract cancer
Watch leading experts in biliary tract cancer discuss the current unmet needs and how targeted treatments can improve patient outcomes.
- Describe the unmet therapeutic needs for patients with biliary tract cancer
- Describe the genetic characteristics and tumour microenvironment of biliary tract cancers
- Explain the supporting data for new and emerging treatments for biliary tract cancers
Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?
Join Dr Alessandra Tedeschi as she highlights the latest data on second-generation Bruton’s tyrosine kinase inhibitors in the management of Waldenström’s macroglobulinaemia.
- Evaluate the new and emerging efficacy data for second-generation BTK inhibitors in patients with WM
- Summarize the adverse events associated with second-generation BTK inhibitors
- Review current management recommendations for people with Waldenström’s macroglobulinaemia
First-line Treatment Options for Renal Cell Carcinoma
Dr Ulka Vaishampayan, from Karmanos Cancer Institute, Wayne State University, MI, USA, discusses first-line treatment options for renal cell carcinoma, including the promising findings from the PROCLAIM registry, which suggest that high dose interleukin-2 is safe and effective before targeted therapy and immune checkpoint blockade.
Realising the Promise of Cell Therapy – The Automated In-house CAR T cell Manufacturing System
Chimeric antigen receptor T cells are providing us with a new option for the treatment of B cell malignancies that are non-responsive to standard therapies. Trial results and the potential of this new technology to treat a wider range of cancers are discussed in this Insight.
FOREWORD – EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 16 ISSUE 1 – SUMMER 2020
European Oncology & Haematology. 2020;16(1):11
Welcome to the summer edition of European Oncology & Haematology. The COVID-19 pandemic has had a devastating impact on cancer and other illness care. In addition to the heightened susceptibility of patients with cancer to infections, lockdown has resulted in delayed screening and reduced treatment of early-stage disease. However, things are starting to move in the […]
Immunotherapy in Advanced Prostate Cancer
European Oncology & Haematology. 2020;16(1):44–50 DOI: https://doi.org/10.17925/EOH.2020.16.1.44
Prostate cancer is the second most common cause of cancer mortality in men, with most deaths occurring as a result of metastatic disease that has become resistant to androgen deprivation therapy (ADT).1 Most recently, immunotherapy, in the form of immune checkpoint inhibitors, has been successful in the treatment of a variety of advanced common solid tumours, […]
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy
European Oncology & Haematology. 2020;16(1):39-43 DOI: https://doi.org/10.17925/EOH.2020.16.1.39
Historically, chemotherapy represented the only available treatment for patients with advanced non-small-cell lung cancer (NSCLC) who did not show any target molecular driver, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or the receptor tyrosine kinase ROS1. Unfortunately, limited efficacy was reported using chemotherapy alone.1 The advent of immunotherapy, a treatment based on […]
ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases
European Oncology & Haematology. 2020;16(1):18-21 DOI: https://doi.org/10.17925/EOH.2020.16.1.18
At initial diagnosis of metastatic disease, central nervous system (CNS) metastases are present in 22–33% of patients with anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC). After crizotinib failure, the incidence can reach up to 70%, compared with 40% in all comers.1 The presence of CNS disease is an indicator of poor prognosis in […]
Want To Know More About Our Journals?
Taking a balanced and practical view of the current clinical landscape in Oncology is at the heart of touchONCOLOGY and the journals we produce.
The European Oncology & Haematology and Oncology & Hematology Review (US) are free-to-access, peer reviewed journals that aim to provide balanced and objective articles relevant to the day-to-day clinical setting.
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!